Experiencia de un Hospital Universitario en el manejo de purpura trombótico trombocitopénico-microangiopatía trombótica no inmune refractaria o en recaída tratado con Rituximab

Resumen

Thrombotic thrombocytopenic purpura, an immune / non-immune thrombotic microangiopathy (TTP / TMA) is associated with high morbidity and mortality, even with appropriate treatment. In patients refractory to standard treatment with plasmapheresis there is no certainty about the best therapeutic strategy. This report shows our experience in eight refractory patients who survived after treatment with rituximab.